Inform Diagnostics, a Fulgent Genetics company, announced that the acquisition of Bako Diagnostics was completed on March 17. Fulgent is an innovative leader in the clinical diagnostic and pathology fields. The acquisition underscores the company’s unwavering commitment to the podiatric medical community and strengthens its leadership position within it for years to come. This new chapter ensures the company’s continued innovation, digital capabilities, enhanced efficiency, and test menu expansion.
Bako Diagnostics will continue to serve the podiatric medical community in the same manner it has for many years.
